Skip directly to site content

Panel:   Enterobacterales Carbapenem Breakpoint (BIT)
AR Bank # 0029 Proteus mirabilis
Study ID: BIT-29

Biosample Accession #: SAMN04014870

MLST: Unknown

MICs obtained by broth microdilution. Modal MIC is reported.

MIC results for each antimicrobial agent for an isolate may commonly be ± 1 log2 (doubling dilution) different than what is posted on the FDA & CDC AR Bank website because this is the normal technical variability of antimicrobial susceptibility testing (see J. H. Jorgensen. 1993. J Clin Microbiol. Vol 31[11]: 2841-2844).

Panel:  Enterobacterales Carbapenem Breakpoint (BIT)  |  GN7F ARLN (Custom)  |  Piperacillin-tazobactam +aminoglycosides for Enterobacterales (PTA) (Custom)

MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin 4S
Ampicillin <=1S
Ampicillin/sulbactam 12S
Aztreonam <=2S
Cefazolin 8R
Cefepime <=0.5S
Cefotaxime <=1S
Cefotaxime/clavulanic acid 1<=0.5---
Cefoxitin 4S
Ceftazidime <=1S
Ceftazidime/avibactam 1<=0.5S
Ceftazidime/clavulanic acid 1<=0.5---
Ceftolozane/tazobactam 1<=0.5S
Ceftriaxone <=1S
Ciprofloxacin <=0.25S
Colistin 5>8R
Doripenem 1S
Eravacycline 21---
Ertapenem 0.25S
Gentamicin 1S
Imipenem 4R
Imipenem+chelators 34---
Levofloxacin <=0.25S
Meropenem 0.5S
Meropenem-vaborbactam 1<=0.5S
Nitrofurantoin 128R
Piperacillin/tazobactam 1<=4S
Plazomicin 4I
Tetracycline >32R
Tigecycline 2 42R
Tobramycin 1S
Trimethoprim/sulfamethoxazole 10.5S
S – I –R Interpretation (INT) derived from CLSI 2023 M100 S33

1 Reflects MIC of first component
2 Based on FDA break points
3 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
4 The interpretation of resistant is due to intrinsic resistance for this species-drug combination rather than the MIC. Refer to CLSI M100 for more information about intrinsic resistance
5 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
Molecular Mechanisms of Resistance
Tetracyclines tet(J)
AR gene prediction was performed using ARG-ANNOT, ResFinder and NCBI (ResGANNCBI) databases accessed on 2021-05-07. AR drug classes are assigned according to these databases. This analysis does not include mutations that may result in antibiotic resistance or resistance determinants added to newer versions of used database or other antimicrobial resistance gene databases. For resistance determinant detection, 99-100% sequence identity and 100% sequence coverage from GAMMA and SRST2 was used. GAMMA uses amino acid sequence to assign gene alleles from assemblies; SRST2 uses nucleotide sequence to assign gene alleles from sequencing reads. Biosample accession numbers have been provided so that users can analyze the data on their own if so desired. *Presence of Efflux Pump may not be associated with resistance. *MLST Type (and scheme), as determined by Torsten Seemann's MLST program. For Enterobacterales, the Pasteur MLST schemes are used except for E. coli for which both the Pasteur and Achtman schemes are reported. SUB=novel MLST identified and "submitted".
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

Temperature: 35°C
Atmosphere: Aerobic


Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.

Storage Temperature & Biosafety

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.

This product is sent with the condition that you are responsible for its safe storage, handling, and use. All materials are the property of the Centers for Disease Control and Prevention (CDC) and have been made available on behalf of the Food and Drug Administration (FDA). This material is not for use in human subjects and may not be redistributed. While CDC uses reasonable efforts to include accurate and up-to-date information on this product sheet, CDC makes no warranties or representations as to its accuracy. CDC is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the Standard Letter Agreement (SLA) for further details regarding the use of this product.
Isolate History
Date Action Performed
10/14/22MIC was updated with a new value for Amikacin: from 8 to 4
04/22/22MIC was updated with a new value
04/22/22MIC was updated with a new value
01/04/22Interpretation was updated with a new value
01/04/22MIC was updated with a new value
04/20/21MIC was updated with a new value
09/22/20MIC was updated with a new value
06/17/20MIC was updated with a new value
06/05/20MIC was updated with a new value
05/26/20MIC was updated with a new value
05/26/20Drug was added
03/06/20MIC was updated with a new value
03/02/20MIC was updated with a new value
03/02/20Drug was added
06/12/19MIC was updated with a new value
06/12/19Drug was added
05/22/19Isolate Characteristics was changed
05/22/19MIC was updated with a new value
05/22/19Drug was added
05/22/19CarbaNP changed
05/22/19mCIM changed
Top of Page